**Author details**

#### Artur Jurczyszyn

Department of Haematology University Hospital, Cracow, Poland

### **References**


[8] Badros A., Porter N., Zimrin A. *Bevacizumab therapy for POEMS syndrome*. Blood 2005; 106: 1135.

women are usually affected. Autosomal inheritance with low gene *penetrance* is believed to be responsible for the onset of the disease. The risk of familial gammopathy of undeter‐ mined significance is slightly higher, although still small. Had there been at least two cases of MM in first or second-degree relatives, an annual immunoelectrophoresis of the urine and serum protein in people 40 years and over would be recommended. If MM had occur‐ red in anyone under 40 years old, the test would be recommended to relatives 35 years and

The described forms of MM are extremely rare. They are an important diagnostic problem because of their atypical clinical manifestation. The course of the disease is usually aggres‐ sive and the prognosis is serious. It is therefore essential that it be quickly and accurately diagnosed. The lack of prospective studies of large groups of patients is an additional prob‐ lem. This makes these atypical clinical forms a therapeutic as well as a diagnostic challenge.

[1] Adam Z. et al. IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezo‐ mib, cyclophosphamide and dexamethasone regimen. Wien Klin Wochenschr 2010;

[3] Alexander D.D. et al. *Multiple myeloma: a review of the epidemiologic literature.* Int J Can‐

[4] Ali R. et al. Efficacy of bortezomib in combination chemotherapy on secondary plas‐

[5] Arimura K., Hashiguchi T. *Crow-Fukase syndrome: clinical features, pathogenesis and treatment in Japan*. W: Yamamura T., Kira J., Tabira T. (red.) *Current topics in neuroim‐*

[6] Avet-Loiseau H. et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and

[7] Bai L.Y. et al. Acalculous cholecystitis mimicking plasma cell leukemia. Ann Hematol

nonsecretory multiple myeloma variants. Blood 2003; 101: 1570–1571.

[2] Albarracin F., Fonseca R. *Plasma cell leukemia.* Blood Rev 2011 Feb 2.

ma cell leukemia. Leuk Lymphoma 2007; 48: 1426–1428.

Department of Haematology University Hospital, Cracow, Poland

over [Gerkes et al. 2007].

252 Multiple Myeloma - A Quick Reflection on the Fast Progress

**Author details**

Artur Jurczyszyn

**References**

122: 311–314.

cer 2007; 120 (suppl. 12): 40–61.

*munology*. Bologna 2007: 241–245.

2006; 85: 487–488.


[25] Fonseca R. et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558.

[42] Jimenez-Zepeda V.H., Dominguez V.J. *Plasma cell leukemia: a rare condition.* Ann Hem‐

Rare Manifestations of Multiple Myeloma http://dx.doi.org/10.5772/53385 255

[43] Johnston R.E., Abdalla S.H. *Thalidomide in low doses is effective for the treatment of resist‐ ant or relapsed multiple myeloma and for plasma cell leukaemia.* Leuk Lymphoma 2002; 43:

[44] Kang K., Chu K., Kim D.E. et al. *POEMS syndrome associated with ischemic stroke*. Arch

[45] Katodritou E. et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res 2009;

[46] Kelly J.J. Jr., Kyle R.A., Miles J.M., Dyck P.J. *Osteosclerotic myeloma and peripheral neu‐*

[47] Kuliszkiewicz-Janus M. et al. Immunoglobulin D myeloma – problems with diagnos‐ ing and staging (own experience and literature review). Leuk Lymphoma 2005; 46:

[48] Kyle R.A. et al. Review of 1027 patients with newly diagnosed multiple myeloma.

[49] Kyle R.A., Rajkumar S.V. *Criteria for diagnosis, staging, risk stratification and response as‐*

[51] MacLennan I.C. *In which cells does neoplastic transformation occur in myelomatosis?* Curr

[53] Maisnar V. et al. High-dose chemotherapy followed by autologous stem cell trans‐ plantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplant

[55] Morris C. et al. Efficacy and outcome of autologous transplantation in rare myelo‐

[56] Musto P. et al. Efficacy and safety of bortezomib in patients with plasma cell leuke‐

[57] Musto P. et al. Salvage therapy with lenalidomide and dexamethasone in relapsed

[58] Nakanishi T., Sobue I., Toyokura Y. et al. *The Crow-Fukase syndrome: a study of 102 cas‐*

primary plasma cell leukemia. Leuk Res 2008; 32: 1637–1638.

atol 2006; 85: 263–267.

Neurol 2003; 60: 745–749.

*ropathy*. Neurology 1983; 33: 202–210.

Mayo Clin Proc 2003; 78: 21–33.

*sessment of multiple myeloma*. Leukemia 2009; 23: 3–9.

Top Microbiol Immunol 1992; 182: 209–214.

mas. Haematologica 2010; 95: 2126–2133.

*es in Japan*. Neurology 1984; 34: 712–720.

mia. Cancer 2007; 109: 2285–2290.

[50] Lynch H.T. et al. *Familial myeloma.* N Engl J Med 2008; 359: 152–157.

[52] Macro M. et al. *IgE multiple myeloma.* Leuk Lymphoma 1999; 32: 597–603.

[54] Merlini G., Stine M.J. *Dangerous small B-cell clones*. Blood 2006; 108: 2520–2530.

351–354.

33: 1137–1140.

1029–1037.

2008; 41: 51–54.


[42] Jimenez-Zepeda V.H., Dominguez V.J. *Plasma cell leukemia: a rare condition.* Ann Hem‐ atol 2006; 85: 263–267.

[25] Fonseca R. et al. Genetics and cytogenetics of multiple myeloma: a workshop report.

[26] Garcia-Sanz R. et al. Primary plasma cell leukemia: clinical, immunophenotypic,

[27] Ganti A.K., Pipinos I., Culcea E. et al. *Successful hematopoietic stem-cell transplantation inmulticentric Castleman disease complicated by POEMS syndrome*. Am J Hematol 2005;

[28] Gawoski J.M., Ooi W.W. *Dengue fever mimicking plasma cell leukemia.* Arch Pathol Lab

[29] Gerkes E.H. et al. Familial multiple myeloma: report on two families and discussion

[30] Gertz M.A., Lacy M.Q., Dispenzieri A. et al. *Stem cell transplantation for the manage‐*

[31] Gherardi R.K., Belec L., Soubrier M. et al. *Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome*. Blood 1996; 87: 1458–1465.

[32] Gherardi R.K., Malapert D., Degos J.D. *Castleman disease – POEMS syndrome overlap*

[33] Hagihara M. et al. An unusual case of IgE-multiple myeloma presenting with sys‐ temic amyloidosis 2 years after cervical plasmacytoma resection. Int J Hematol 2010;

[34] Han X. et al. Lymphoma survival patterns by WHO subtype in the United States,

[35] Harati A. et al. Skin disorders in association with monoclonal gammopathies. Eur J

[36] Hitoshi S., Suzuki K., Sakuta M. *Elevated serum interleukin-6 in POEMS syndrome re‐*

[37] Homan, H. et al. IgD multiple myeloma with renal involvement: case report. Jpn J

[39] Iwashita H., Ohnishi A., Asada M. et al. *Polyneuropathy, skin hyperpigmentation, edema, and hypertrichosis in localized osteosclerotic myeloma*. Neurology 1977; 27: 675–681.

[40] Jaccard A., Royer B., Bordessoule D. et al. *High-dose therapy and autologous blood stem*

[41] Jancelewicz Z. et al. *IgD multiple myeloma. Review of 133 cases.* Arch Intern Med 1975;

[38] Invernizzi F. et al. *A new case of IgE myeloma.* Acta Haematol 1991; 85: 41–44.

*cell transplantation in POEMS syndrome*. Blood 2002; 99: 3057–3059.

of screening options. Hered Cancer Clin Pract 2007; 5: 72–78.

[letter; comment]. Ann. Intern Med 1991; 114: 520–521.

1973–2003. Cancer Causes Control, 2008; 19: 841–858.

*flects the activity of the disease*. Intern Med 1994; 33: 25–33.

*ment of primary systemic amyloidosis*. Am J Med 2002; 113: 549–555.

DNA ploidy, and cytogenetic characteristics. Blood 1999; 93: 1032–1037.

Cancer Res 2004; 64: 1546–1558.

254 Multiple Myeloma - A Quick Reflection on the Fast Progress

Med 2003; 127: 1026–1027.

79: 206–210.

92: 381–385.

Med Res 2005; 10: 93–104.

Med 1990; 29: 212–215.

135: 87–93.


[59] Nakano A., Mitsui T., Endo I. et al. *Solitary plasmacytoma with VEGF overproduction: report of a patient with polyneuropathy*. Neurology 2001; 56: 818–819.

[75] Soubrier M., Dubost J.J., Serre A.F. et al. *Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor*. Arthritis Rheum

Rare Manifestations of Multiple Myeloma http://dx.doi.org/10.5772/53385 257

[76] Straume O., Bergheim J., Ernst P. *Bevacizumab therapy for POEMS syndrome*. Blood

[77] Szturz P. et al. *Lenalidomide: a new treatment option for Castleman disease*. Leuk Lym‐

[78] Terpos E. et al. Plasmacytoma relapses in the absence of systemic progression posthigh-dose therapy for multiple myeloma. Eur J Haematol 2005; 75: 376–383.

[79] Tiedemann R.E. et al. *Genetic aberrations and survival in plasma cell leukemia.* Leukemia

[80] Watanabe O., Maruyama I., Arimura K. et al. *Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome*.

[81] Yeh K.H. et al. Long-term disease-free survival after autologous bone marrow trans‐ plantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific

1997; 40: 786–787.

2006; 107: 4973–4974.

2008; 22: 1044–1052.

phoma 2012; 53: 2089–2091.

Muscle Nerve 1998; 21: 1390–1397.

probes. Br J Haematol 1995; 89: 914–916.


[75] Soubrier M., Dubost J.J., Serre A.F. et al. *Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor*. Arthritis Rheum 1997; 40: 786–787.

[59] Nakano A., Mitsui T., Endo I. et al. *Solitary plasmacytoma with VEGF overproduction:*

[60] Orefice G., Morra V.B., De Michele G. et al. *POEMS syndrome: clinical, pathological and*

[61] Paydas S. et al. *Sweet's syndrome associated with G-CSF.* Br J Haematol 1993; 85: 191–

[62] Petrucci M.T. et al. Thalidomide does not modify the prognosis of plasma cell leuke‐ mia patients: experience of a single center. Leuk Lymphoma 2007; 48: 180–182.

[63] Rajkumar S.V. *Multiple myeloma: 2011 update on diagnosis, risk-stratification, and man‐*

[64] Radfar L. et al. Paraneoplastic epidermolysis bullosa acquisita associated with multi‐

[65] Reece D.E. et al. Outcome of patients with IgD and IgM multiple myeloma undergo‐ ing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR

[66] Reitan J.B., Pape E., Fossa S.D. et al. *Osteosclerotic myeloma with polyneuropathy*. Acta

[67] Rose C., Zandecki M., Copin M.C. et al. *POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromoso‐*

[68] Sanada S., Ookawara S., Karube H. et al. *Marked recovery of severe renal lesions in PO‐ EMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell*

[69] Schop R.F. et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytoge‐

[70] Schuster S.R. et al. IgM multiple myeloma: disease definition, prognosis, and differ‐ entiation from Waldenstrom's macroglobulinemia. Am J Hematol 2010; 85: 853–855.

[71] Sharma M. et al. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol 2010; 85: 502–504.

[72] Sher T. et al. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br

[73] Shimamoto Y., Anami Y., Yamaguchi M. *A new risk grouping for IgD myeloma based on*

[74] Singh D., Kumar L. *Myelomatous ascites in multiple myeloma.* Leuk Lymphoma 2005;

*analysis of 165 Japanese patients.* Eur J Haematol 1991; 47: 262–267.

*mal aberrations of bone marrow plasma cells*. Leukemia 1997; 11: 1318–1323.

*report of a patient with polyneuropathy*. Neurology 2001; 56: 818–819.

*immunological study of a case*. Neurol Res 1994; 16: 477–480.

*agement*. Am J Hematol 2011; 86: 57–65.

256 Multiple Myeloma - A Quick Reflection on the Fast Progress

Med Scand 1980; 208: 137–144.

net 2006; 169: 150–153.

J Haematol 2010; 150: 418–427.

46: 631–632.

ple myeloma. Spec Care Dentist 2006; 26: 159–163.

*transplantation*. Am J Kidney Dis 2006; 47: 672–679.

Study. Clin Lymphoma Myeloma Leuk 2010; 10: 458–463.

192.


**Chapter 13**

**Pain and Multiple Myeloma**

http://dx.doi.org/10.5772/55528

**1. Introduction**

any M-protein present.

bone biopsies [1].

vertebrae are reasons of severe myeloma pain.

components can be easily involved in myeloma pain [2].

Emine Ozyuvaci, Onat Akyol and Tolga Sitilci

Additional information is available at the end of the chapter

Multiple myeloma is a plasma cell malignancy characterized with clonal expansion of malignant plasma cells within the bone marrow and followed by osteolytic bone disease. It accounts for approximately 1% of all malignant diseases and represents about 10% of hema‐ tologic malignancies. Data from cloning and gene-sequencing studies strongly imply that the malignant clone in MM arises from a late cell in B-cell development. Investigation of a patient with suspected myeloma should include the screening tests. Electrophoresis of serum and concentrated urine should be performed, followed by immunofixation to confirm and type

The common clinical presentations are fatigue and bone pain with or without associated fractures or infection. Mechanical impacts like intraosseous tumor pressure, microfractures, periost irritation, muscle spasm, nerve entrapment and compression of nerves by the collapsed

Radiographic skeletal survey and bone marrow aspiration and biopsy are performed for diagnosis. Angtuaco EJ et al reported a radiologic review and explained that MR imaging bone marrow surveys in patients with MM demonstrate the broad spectrum of involvement, the results of treatment, the areas of potential complications, and the sites of focal disease for safe

Pain characteristics clinically can be summarised as, pain is worse in supine position, especially at night or awakens from sleep, band like distribution around body, not relieved with rest and nonsteroidal anti-inflammatory drugs (NSAIDS), associated symptoms like fever, weight loss and progressive neurologic deficite in lower extremities. Somatic, visceral and neuropathic

Chronic pain is extremely prevalent among patients with cancer. According to studies cancer pain can be relieved in more than 70% of patients using a simple opioid- based regimen.

and reproduction in any medium, provided the original work is properly cited.

© 2013 Ozyuvaci et al.; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
